In Brief

Appropriations subcommittee largely ignores FDA; analysts predict lower Novartis OTC sales; France tightens advertising rules; NAD weighs in on Lunada claims; Global Biotechnologies supplements seized; Tetley tea faces lawsuit for antioxidant claims; more news In Brief.

Democrats complain planned cuts to FDA funding could hurt public health, but offered no change to the agency’s proposed fiscal year 2013 appropriation during a mark-up June 6. The House Appropriations Subcommittee on Agriculture, Rural Development, FDA and Related Agencies discussed FDA in opening comments. Rep. Rosa DeLauro, D-Conn., a former chair of the subcommittee, said underfunding FDA would risk Americans’ health. But Rep. Sam Farr, D-Calif., praised an increase in food safety funding and did not mention the proposed cuts among those that went “beyond lean.” FDA would receive $16.3 million less in budget authority, meaning non-user fee funding, in FY 2013 compared to FY 2012. The cut is less than 1%, but also is $44 million less than the FY 2013 funding bill under consideration in the Senate. The House bill would rescind $47.7 million in unobligated balances from prior-year discretionary funds, which a committee staffer said was common practice. Overall, the House bill would give FDA $3.835 billion in treasury and user fee money, while the Senate bill would allocate $3.878 billion.

The Consumer Healthcare Products Association presses the Senate to follow the House’s lead and repeal a provision of the Patient Protection and Affordable Care Act that blocks consumers from paying...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Marketing & Advertising

Pharma DTC Ad Tax Break Targeted By US HHS, Congress

 

Health and Human Services Secretary Robert F. Kennedy Jr. said a policy that would remove the tax write-off for pharma advertising expenses would be coming in a few weeks.

Sarfez Pharma’s Promotional Claims For Diuretic Soaanz Draw US FDA Warning Letter

 
• By 

Webpages, a healthcare professional pamphlet and a medical conference exhibit booth panel make unsupported comparative superiority claims about generic torsemide products and misrepresent risks, the Office of Prescription Drug Promotion says in its first warning letter of 2025.

Mayne’s Nextstellis Promo Wrong To Suggest Better Safety Than Other Contraceptives, FDA Says

 
• By 

A professional slide deck for the drospirenone/estetrol oral contraceptive inappropriately suggests it is safer than other estrogen-containing products and understates risks, Office of Prescription Drug Promotion said in the first “untitled” letter issued since reductions-in-force.

Are Bigger Ad Policy Changes Coming After US FDA’s Drug Promotion Office Hit Hard By Layoffs?

 
• By 

The loss of policy analyst, legal, project manager and social scientist positions has experts wondering if the Trump Administration is eyeing a broader effort to limit DTC advertising. The OPDP layoffs are expected to result in delayed reviews of promotional pieces.

More from Compliance

Sarfez Pharma’s Promotional Claims For Diuretic Soaanz Draw US FDA Warning Letter

 
• By 

Webpages, a healthcare professional pamphlet and a medical conference exhibit booth panel make unsupported comparative superiority claims about generic torsemide products and misrepresent risks, the Office of Prescription Drug Promotion says in its first warning letter of 2025.

US FDA Legislative Lead Calls For User Fee Reforms As Renewal Talks Near

 

Deputy FDA Commissioner Grace Graham acknowledged the importance of user fees, while also calling for restructuring. She also said part of MAHA's mission is to reexamine uses of drugs not supported by data.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.